|
🐜
|
Pivotal role of mTOR signaling in hepatocellular carcinoma.
26 auth.
A. Villanueva,
Derek Y. Chiang,
P. Newell,
J. Peix,
S. Thung,
Clara Alsinet,
V. Tovar,
S. Roayaie,
B. Mínguez,
M. Solé,
C. Battiston,
Stijn Van Laarhoven,
M. Fiel,
Analisa Di Feo,
Y. Hoshida,
...
S. Yea,
S. Toffanin,
A. Ramos,
J. Martignetti,
V. Mazzaferro,
J. Bruix,
S. Waxman,
M. Schwartz,
M. Meyerson,
S. Friedman,
J. Llovet
|
9 |
2008 |
9
🐜
|
|
🐜
|
Focal gains of VEGFA and molecular classification of hepatocellular carcinoma.
25 auth.
Derek Y. Chiang,
A. Villanueva,
Y. Hoshida,
J. Peix,
P. Newell,
B. Mínguez,
A. Leblanc,
D. J. Donovan,
S. Thung,
M. Solé,
V. Tovar,
Clara Alsinet,
A. Ramos,
J. Barretina,
S. Roayaie,
...
M. Schwartz,
S. Waxman,
J. Bruix,
V. Mazzaferro,
A. Ligon,
V. Najfeld,
S. Friedman,
W. Sellers,
M. Meyerson,
J. Llovet
|
9 |
2008 |
9
🐜
|
|
🐜
|
Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes.
23 auth.
D. Sia,
Y. Hoshida,
A. Villanueva,
S. Roayaie,
J. Ferrer,
B. Tabak,
J. Peix,
M. Solé,
V. Tovar,
Clara Alsinet,
...
H. Cornellà,
Brandy Klotzle,
Jian-Bing Fan,
C. Cotsoglou,
S. Thung,
J. Fuster,
S. Waxman,
J. García-Valdecasas,
J. Bruix,
M. Schwartz,
R. Beroukhim,
V. Mazzaferro,
J. Llovet
|
8 |
2013 |
8
🐜
|
|
🐜
|
Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma.
19 auth.
A. Villanueva,
Y. Hoshida,
C. Battiston,
V. Tovar,
D. Sia,
Clara Alsinet,
H. Cornellà,
A. Liberzon,
M. Kobayashi,
H. Kumada,
...
S. Thung,
J. Bruix,
P. Newell,
Craig S. April,
Jian-Bing Fan,
S. Roayaie,
V. Mazzaferro,
M. Schwartz,
J. Llovet
|
8 |
2011 |
8
🐜
|
|
🦁
|
IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage.
16 auth.
V. Tovar,
Clara Alsinet,
A. Villanueva,
Y. Hoshida,
Derek Y. Chiang,
M. Solé,
S. Thung,
S. Moyano,
S. Toffanin,
B. Mínguez,
...
L. Cabellos,
J. Peix,
M. Schwartz,
V. Mazzaferro,
J. Bruix,
J. Llovet
|
7 |
2010 |
7
🦁
|
|
🐜
|
MicroRNA-based classification of hepatocellular carcinoma and oncogenic role of miR-517a.
20 auth.
S. Toffanin,
Y. Hoshida,
A. Lachenmayer,
A. Villanueva,
L. Cabellos,
B. Mínguez,
R. Savić,
S. Ward,
S. Thung,
Derek Y. Chiang,
...
Clara Alsinet,
V. Tovar,
S. Roayaie,
M. Schwartz,
J. Bruix,
S. Waxman,
S. Friedman,
T. Golub,
V. Mazzaferro,
J. Llovet
|
7 |
2011 |
7
🐜
|
|
🐜
|
Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo.
25 auth.
P. Newell,
S. Toffanin,
A. Villanueva,
Derek Y. Chiang,
Derek Y. Chiang,
B. Mínguez,
L. Cabellos,
R. Savić,
Y. Hoshida,
Y. Hoshida,
K. Lim,
P. Melgar-Lesmes,
S. Yea,
J. Peix,
K. Deniz,
...
M. Fiel,
S. Thung,
Clara Alsinet,
V. Tovar,
V. Mazzaferro,
J. Bruix,
S. Roayaie,
M. Schwartz,
S. Friedman,
J. Llovet
|
7 |
2009 |
7
🐜
|
|
🐬
|
Intrahepatic cholangiocarcinoma: pathogenesis and rationale for molecular therapies
D. Sia,
V. Tovar,
Agrin Moeini,
J. Llovet
|
7 |
2013 |
7
🐬
|
|
🐜
|
Palbociclib (PD-0332991), a selective CDK4/6 inhibitor, restricts tumour growth in preclinical models of hepatocellular carcinoma
15 auth.
J. Bollard,
Verónica Miguela,
M. R. D. Galarreta,
A. Venkatesh,
C. B. Bian,
Mark P. Roberto,
V. Tovar,
D. Sia,
Pedro Molina-Sánchez,
Christie B Nguyen,
...
S. Nakagawa,
J. Llovet,
J. Llovet,
Y. Hoshida,
A. Lujambio
|
7 |
2016 |
7
🐜
|
|
🐬
|
Cancer gene discovery in hepatocellular carcinoma.
L. Zender,
A. Villanueva,
V. Tovar,
D. Sia,
Derek Y. Chiang,
J. Llovet
|
7 |
2010 |
7
🐬
|
|
🐜
|
Generation and phenotypic analysis of sigma receptor type I (σ1) knockout mice
14 auth.
Francina Langa,
X. Codony,
V. Tovar,
Alfonso J. Lavado,
E. Giménez,
P. Cozar,
Marta Cantero,
A. Dordal,
E. Hernández,
Raquel Pérez,
...
Xavier Monroy,
D. Zamanillo,
X. Guitart,
L. Montoliu
|
7 |
2003 |
7
🐜
|
